Chapter 30- Drug Therapy to Decrease Histamine Effects

Abrams' Clinical Drug Therapy Rationales for Nursing Practice by Geralyn Frandsen

$2.99

Chapter 30- Drug Therapy to Decrease Histamine Effects

 

Complete Chapter Questions With Answers

 

Sample Questions Are Posted Below

 

1. A patient is stung by a bee. What is the chemical mediator released in immune and inflammatory response to the bee sting?
  A) Norepinephrine
  B) Mast cells
  C) Epinephrine
  D) Histamine
  Ans: D
  Feedback:
  Histamine is the chemical mediator released in immune and inflammatory response to the bee sting.

 

 

2. A patient is experiencing allergy symptoms after being exposed to environmental dust. This reaction involves the action of histamine, which is released by what cells?
  A) Lymphocytes
  B) CD4 T cells
  C) Basophils
  D) Platelets
  Ans: C
  Feedback:
  Histamine is discharged from mast cells and basophils in response to certain stimuli, such as allergic reactions, cellular injury, and extreme cold. Lymphocytes and platelets do not release histamine.

 

 

3. A patient is being administered epinephrine for the treatment of anaphylaxis. This patient is experiencing what type of hypersensitivity reaction?
  A) Type I
  B) Type II
  C) Type III
  D) Type IV
  Ans: A
  Feedback:
  Anaphylaxis is a type I response, which can be mild or life threatening.

 

 

4. An elderly patient is given diphenhydramine (Benadryl) for allergic response to mold. The nurse should consequently assess the patient for
  A) anticholinergic effects.
  B) dysrhythmias.
  C) increased muscle tone.
  D) respiratory depression.
  Ans: A
  Feedback:
  Diphenhydramine (Benadryl) is the prototype of first-generation antihistamines and causes a high incidence of drowsiness and anticholinergic effects. It is not associated with dysrhythmias, increased muscle tone, or respiratory depression.

 

 

5. A second-generation H1 receptor antagonist antihistamine formulated as a nasal spray for topical use is
  A) chlorpheniramine (Chlor-Trimeton).
  B) clemastine (Tavist).
  C) cyproheptadine (Periactin).
  D) azelastine (Astelin).
  Ans: D
  Feedback:
  Azelastine (Astelin) and olopatadine (Patanol) are second-generation H1 receptor antagonists that have been formulated as nasal sprays for topical use. Each of the other listed drugs is a first-generation H1 receptor antagonist.

 

Additional information

Add Review

Your email address will not be published. Required fields are marked *